164 related articles for article (PubMed ID: 34128760)
21. WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.
Driehuis E; Clevers H
Br J Pharmacol; 2017 Dec; 174(24):4547-4563. PubMed ID: 28244067
[TBL] [Abstract][Full Text] [Related]
22. Wnt signaling in bone metastasis: mechanisms and therapeutic opportunities.
Li X; Yang J; Bao M; Zeng K; Fu S; Wang C; Ye L
Life Sci; 2018 Sep; 208():33-45. PubMed ID: 29969609
[TBL] [Abstract][Full Text] [Related]
23. Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
Mukherjee N; Panda CK
Clin Breast Cancer; 2020 Oct; 20(5):361-370. PubMed ID: 32416986
[TBL] [Abstract][Full Text] [Related]
24. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair.
Jarman EJ; Boulter L
Expert Opin Investig Drugs; 2020 Feb; 29(2):179-190. PubMed ID: 31948298
[No Abstract] [Full Text] [Related]
26. Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.
Madan B; Virshup DM
Mol Cancer Ther; 2015 May; 14(5):1087-94. PubMed ID: 25901018
[TBL] [Abstract][Full Text] [Related]
27. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F; Moussa N; Helmy MW; Haroun M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
[TBL] [Abstract][Full Text] [Related]
29. Small molecules from natural products targeting the Wnt/β-catenin pathway as a therapeutic strategy.
Liu D; Chen L; Zhao H; Vaziri ND; Ma SC; Zhao YY
Biomed Pharmacother; 2019 Sep; 117():108990. PubMed ID: 31226638
[TBL] [Abstract][Full Text] [Related]
30. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.
Gurney A; Axelrod F; Bond CJ; Cain J; Chartier C; Donigan L; Fischer M; Chaudhari A; Ji M; Kapoun AM; Lam A; Lazetic S; Ma S; Mitra S; Park IK; Pickell K; Sato A; Satyal S; Stroud M; Tran H; Yen WC; Lewicki J; Hoey T
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11717-22. PubMed ID: 22753465
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic Manipulation of Wnt Signaling and Cancer Stem Cells.
Duchartre Y; Kim YM; Kahn M
Methods Mol Biol; 2017; 1613():463-478. PubMed ID: 28849572
[TBL] [Abstract][Full Text] [Related]
32. [Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway].
Nishiya N
Yakugaku Zasshi; 2017; 137(2):133-136. PubMed ID: 28154320
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic.
Laranjeira AB; Yang SX
Expert Opin Drug Discov; 2016 Nov; 11(11):1071-1080. PubMed ID: 27626707
[TBL] [Abstract][Full Text] [Related]
34. Wnt Signaling and Drug Resistance in Cancer.
Zhong Z; Virshup DM
Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618
[TBL] [Abstract][Full Text] [Related]
35. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
36. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
Cheng X; Xu X; Chen D; Zhao F; Wang W
Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
[TBL] [Abstract][Full Text] [Related]
38. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
39. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
Haider K; Rahaman S; Yar MS; Kamal A
Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
[No Abstract] [Full Text] [Related]
40. MYC modulators in cancer: a patent review.
Wang XN; Su XX; Cheng SQ; Sun ZY; Huang ZS; Ou TM
Expert Opin Ther Pat; 2019 May; 29(5):353-367. PubMed ID: 31068032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]